secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001193125-24-199416
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA Royalty Q2 net income $16.0M; receives $22.6M cash; acquires Kinnate and Daré rights; posts $9.0M impairment
--------------------------------------------------------------------------------

- Net income $16.0M vs net loss $5.4M in Q2 2023; total income/revenue $11.1M; cash receipts $22.6M.
- Completed acquisition of Kinnate Pharmaceuticals, adding >$9.5M cash and potential royalty streams; acquired Daré's XACIATO, Ovaprene, Sildenafil Cream rights.
- Recorded $9.0M non-cash impairment on Aronora programs; $19.3M gain on Kinnate acquisition, partially offset by $8.1M derivative charge.
- Zevra's arimoclomol received favorable advisory committee vote; FDA PDUFA date Sept 21, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524199416/0001193125-24-199416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524199416/d829744d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-199416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer